home / stock / imgn / imgn news

IMGN News and Press, ImmunoGen Inc. From 02/04/24

Stock Information
Company Name: ImmunoGen Inc.
Stock Symbol: IMGN
Market: NASDAQ
Website: immunogen.com
Menu
IMGN IMGN Quote IMGN Short IMGN News IMGN Articles IMGN Message Board
Get IMGN Alerts

News, Short Squeeze, Breakout and More Instantly...
IMGN - Pharma giants turn to China in search of targeted cancer drugs

2024-02-04 12:00:49 ET More on AbbVie, Johnson & Johnson, etc. AbbVie Inc. (ABBV) Q4 2023 Earnings Call Transcript Merck & Co., Inc. 2023 Q4 - Results - Earnings Call Presentation Merck & Co., Inc. (MRK) Q4 2023 Earnings Call Transcript AbbVie cit...
IMGN - AbbVie posts Q4 revenue beat despite Humira patent cliff

2024-02-02 08:22:44 ET More on AbbVie AbbVie Q4 Earnings Preview: Few Clouds On Horizon Thanks To Masterful Management (Rating Upgrade) AbbVie Inc. (ABBV) JPMorgan 42nd Annual Healthcare Conference AbbVie: Still Expensive Despite The Great M&A Acumen AbbV...

IMGN - AbbVie Q4 in focus as Humira patent cliff reaches one-year mark

2024-02-01 12:10:01 ET More on AbbVie AbbVie Q4 Earnings Preview: Few Clouds On Horizon Thanks To Masterful Management (Rating Upgrade) AbbVie Inc. (ABBV) JPMorgan 42nd Annual Healthcare Conference AbbVie: Still Expensive Despite The Great M&A Acumen AbbV...

IMGN - Outperform Recommendation Issued On IMGN By William Blair

2024-01-29 14:30:02 ET William Blair analyst issues OUTPERFORM recommendation for IMGN on January 29, 2024 02:04PM ET. IMGN was trading at $29.405 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, ...
IMGN - AbbVie raised to Outperform at William Blair ahead of earnings

2024-01-29 08:30:18 ET More on AbbVie AbbVie Inc. (ABBV) JPMorgan 42nd Annual Healthcare Conference AbbVie: Still Expensive Despite The Great M&A Acumen Investor's Dilemma: AbbVie Stock Amidst U.S. Election And Humira Decline Big Pharma earnings season in...

IMGN - Catalyst watch: Apple earnings, Boeing on the hot seat, FOMC meeting and Amer Sports IPO

2024-01-26 15:00:55 ET More on SPDR S&P 500 ETF Trust SPY: Black Swan Hiding In Plain Sight 2024 Analyst Outlook: Jussi Askola On Being Selective With REITs, Dividend Investing SPY Is At Its Highest Risk Level (Technical Analysis) Investors withdraw capit...

IMGN - How to Take Advantage of moves in (IMGN)

2024-01-09 03:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
IMGN - Johnson & Johnson to acquire ADC developer Ambrx Biopharma for $2B

2024-01-08 07:52:26 ET More on Johnson & Johnson Johnson & Johnson: Overblown Stelara Concerns Distract From Value Johnson & Johnson's Bullish Outlook: Surprising Strength You Shouldn't Overlook Johnson & Johnson: A Defensive Dividend King Set To Outp...

IMGN - J.P. Morgan event in spotlight as biotech M&A, obesity frenzy, AI pick up

2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...

IMGN - AbbVie: Still Expensive Despite The Great M&A Acumen

2024-01-05 09:00:00 ET Summary ABBV's Humira erosion has been well balanced by the robust growth reported by Skyrizi and Rinvoq, implying its ability to maintain a stable top/ bottom line performance ahead. The management has also participated in the aggressive M&A activities ...
Previous 10 Next 10